Line Abildgaard Ryberg

Line Abildgaard Ryberg is an Assistant Professor in the Department of Immunology and Microbiology at the University of Copenhagen's Faculty of Health and Medical Sciences, specializing in virology. Her research focuses on viral mechanisms, antiviral resistance, and drug development for emerging viral pathogens including SARS-CoV-2 and hepatitis C virus.

Dr. Ryberg's research interests span several critical areas in modern virology:

• Mechanisms of viral resistance to antiviral drugs
• Viral evolution under drug pressure
• Molecular virology of coronaviruses and hepatitis C virus
• Development of cell culture systems for viral propagation
• Antiviral drug screening and evaluation

Her recent publications demonstrate a strong focus on understanding how viruses like SARS-CoV-2 develop resistance to antiviral treatments such as remdesivir and nirmatrelvir. Her work bridges molecular virology with practical therapeutic applications, examining how viral mutations affect drug efficacy while maintaining viral fitness across multiple cell culture systems.

Dr. Ryberg's research has garnered significant attention, with multiple publications being picked up by dozens of news outlets, referenced in policy sources, and widely shared on social media platforms including X (formerly Twitter), Facebook, and Bluesky. Her 2023 Nature paper on Hepatitis C virus RNA capping received particular attention, being widely read on Mendeley and referenced in academic discussions.

She collaborates extensively with researchers at the University of Copenhagen, particularly with Jens Bukh, Judith M. Gottwein, and other members of the virology research group. Her work demonstrates a strong interdisciplinary approach connecting basic virology with clinical applications for viral disease treatment.